Sara Tolaney· @stolaney1 · X·· 2 days agoScore90
Body · original
NATALEE: OS data
Adjuvant ribociclib in ER+ breast cancer
6 yr OS HR 0.809 (delta 2.1%)
BCSS: 0.706 (delta 2.6%)
6 yr iDFS HR 0.741 (delta ~5%)
DDFS: HR 0.744
@OncoAlert #ESMO26
2056 views · 15 likes · 11 reposts · 0 replies
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgSource: Sara Tolaney · x.com